Related Experiment Videos
Polyomavirus nephropathy after renal transplantation: a single centre experience
Hyun Chul Kim1, Eun Ah Hwang, Seung Yeup Han
1Department of Internal Medicine, Dongsan Kidney Institute, Keimyung University, Dongsan Medical Center, Daegu, Korea. k780121@dsmc.or.kr
Nephrology (Carlton, Vic.)
|May 10, 2005
Summary
Polyomavirus associated nephropathy (PVN) is a growing concern in kidney transplant patients, often linked to potent immunosuppressants. Early detection and adjusting medications can improve outcomes and reduce graft loss.
Area of Science:
- Nephrology
- Transplant Surgery
- Virology
Background:
- Polyomavirus associated nephropathy (PVN) is increasingly diagnosed in renal transplant recipients.
- PVN is associated with potent immunosuppressive regimens, including tacrolimus and mycophenolate mofetil (MMF).
- PVN is a significant cause of renal allograft failure.
Purpose of the Study:
- To investigate the incidence, clinical course, and outcomes of PVN in renal transplant recipients.
- To evaluate the impact of immunosuppression manipulation on PVN management.
Main Methods:
- Retrospective review of nine renal transplant recipients diagnosed with PVN between October 1998 and July 2003.
- Confirmation of PVN through allograft biopsy and electron microscopy.
- Analysis of clinical records and outcomes following reduction of immunosuppressive therapy.
Main Results:
- The incidence of PVN was 4.9% (9 out of 182 patients).
- All PVN patients were on triple immunosuppression including tacrolimus and MMF.
- Reducing immunosuppression stabilized renal function in seven patients; two experienced graft loss, and two developed acute rejection.
Conclusions:
- PVN can lead to renal allograft dysfunction and loss.
- Routine screening with urine cytology and viral load measurement is recommended for at-risk patients.
- Early diagnosis and adjusted immunosuppression may improve prognosis and reduce graft loss.